[go: up one dir, main page]

BR9909342A - Vacinas adn adjuvadas - Google Patents

Vacinas adn adjuvadas

Info

Publication number
BR9909342A
BR9909342A BR9909342-1A BR9909342A BR9909342A BR 9909342 A BR9909342 A BR 9909342A BR 9909342 A BR9909342 A BR 9909342A BR 9909342 A BR9909342 A BR 9909342A
Authority
BR
Brazil
Prior art keywords
dna vaccines
dna
auxiliary compound
adjuvant
adjuvant dna
Prior art date
Application number
BR9909342-1A
Other languages
English (en)
Inventor
Jean-Christophe Franc Audonnet
Jules Maarten Minke
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9525029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909342(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Sas filed Critical Merial Sas
Publication of BR9909342A publication Critical patent/BR9909342A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"VACINAS ADN ADJUVADAS"<D>. A vacina ADN compreende um ADN desprotegido, incorporando e expressando in vivo uma seq³ência nucleotídica, codificando para um polipeptídeo antigênico, de preferência um gene de um agente patogênico, e pelo menos um composto auxiliar escolhido dentre os polímeros acrílico ou metacrílico e os copolímeros de anidrido maléico e de derivado alcenila. O composto auxiliar é, de preferência, um carbómero ou um EMA(r).
BR9909342-1A 1998-04-03 1999-03-22 Vacinas adn adjuvadas BR9909342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9804409A FR2776928B1 (fr) 1998-04-03 1998-04-03 Vaccins adn adjuves
PCT/FR1999/000666 WO1999051269A1 (fr) 1998-04-03 1999-03-22 Vaccins adn adjuves

Publications (1)

Publication Number Publication Date
BR9909342A true BR9909342A (pt) 2000-12-12

Family

ID=9525029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909342-1A BR9909342A (pt) 1998-04-03 1999-03-22 Vacinas adn adjuvadas

Country Status (17)

Country Link
US (1) US7163926B1 (pt)
EP (1) EP1066055B1 (pt)
JP (1) JP2002510651A (pt)
AR (1) AR037062A1 (pt)
AT (1) ATE353670T1 (pt)
AU (1) AU744964B2 (pt)
BR (1) BR9909342A (pt)
CA (1) CA2327389C (pt)
CY (1) CY1108013T1 (pt)
DE (1) DE69935136T2 (pt)
DK (1) DK1066055T3 (pt)
ES (1) ES2283105T3 (pt)
FR (1) FR2776928B1 (pt)
PL (1) PL194348B1 (pt)
PT (1) PT1066055E (pt)
WO (1) WO1999051269A1 (pt)
ZA (1) ZA992478B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551598B2 (en) 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
CA2470322A1 (en) * 2001-12-14 2003-06-26 Genetronics, Inc. Methods for particle-assisted polynucleotide immunization using a pulsed electric field
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
GB0805356D0 (en) * 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신
BR112014001287B1 (pt) 2011-07-20 2020-12-08 Centre National De La Recherche Scientifique vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
CA2867893C (en) 2012-03-20 2022-09-20 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
AU2013308627B2 (en) 2012-08-30 2016-10-27 Boehringer Ingelheim Animal Health USA Inc. Expression of chimeric KSAC protein and method of producing soluble proteins by high pressure
WO2016210097A1 (en) * 2015-06-23 2016-12-29 The Trustees Of Columbia University In The City Of New York Novel equine parvovirus and uses thereof
MX395520B (es) 2016-06-17 2025-03-26 Boehringer Ingelheim Animal Health Usa Inc Formulaciones inmunogenicas novedosas que comprenden adyuvantes de polimero de acido poliacrilico lineal o ramificado.
CN115836042A (zh) * 2020-07-07 2023-03-21 阿米瑞斯公司 疫苗佐剂及其合成和使用方法
CN114272368A (zh) * 2021-12-16 2022-04-05 成都博宠生物科技有限公司 一种猪瘟和猪伪狂犬二联疫苗及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
ES2052685T3 (es) * 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP0532833A1 (en) * 1991-05-28 1993-03-24 Miles Inc. Vaccine for equine rhinopneumonitis
US5922327A (en) * 1992-06-01 1999-07-13 The University Of Melbourne Equine herpes virus glycoproteins
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US6300118B1 (en) * 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
FR2751226B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP0991767A1 (en) * 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
AU8392898A (en) * 1997-07-14 1999-02-10 Powerject Vaccines, Inc. Method of dna vaccination using dna encoding antigen and encoding il6
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof

Also Published As

Publication number Publication date
CY1108013T1 (el) 2013-09-04
EP1066055B1 (fr) 2007-02-14
DE69935136D1 (de) 2007-03-29
AR037062A1 (es) 2004-10-20
ATE353670T1 (de) 2007-03-15
US7163926B1 (en) 2007-01-16
CA2327389C (en) 2011-06-14
ES2283105T3 (es) 2007-10-16
AU744964B2 (en) 2002-03-07
ZA992478B (en) 2000-10-10
JP2002510651A (ja) 2002-04-09
PL343602A1 (en) 2001-08-27
FR2776928B1 (fr) 2000-06-23
PL194348B1 (pl) 2007-05-31
EP1066055A1 (fr) 2001-01-10
DK1066055T3 (da) 2007-06-11
AU2844899A (en) 1999-10-25
WO1999051269A1 (fr) 1999-10-14
PT1066055E (pt) 2007-05-31
DE69935136T2 (de) 2007-11-29
CA2327389A1 (en) 1999-10-14
FR2776928A1 (fr) 1999-10-08

Similar Documents

Publication Publication Date Title
BR9909342A (pt) Vacinas adn adjuvadas
BR9611845A (pt) Vacina viva recombinante à base de herpesvírus felino de tipo 1 notadamente contra a peritonite infecciosa felina
CY2016020I1 (el) Στελεχη ιου του ερπη για γονιδιακη θepαπεια
ATE141946T1 (de) Hiv-2-virusvarianten
BR9908496A (pt) Vacinas vivas recombinadas e adjuvadas
HUP0300120A3 (en) Altered strain of the modified vaccina virus ankara (mva)
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
NO944245D0 (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
NZ502259A (en) Selectively hardened nail with one axial portion having hardness of at least 40 Rockwell C, and another axial portion having hardness of 35 Rockwell C maximum
DE69931639D1 (en) Ehrlichia canis protein
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
ATE321844T1 (de) Rekombinanter schweinepockenvirus
BR0012512B1 (pt) genes de calicivìrus felino e vacinas notadamente vacinas recombinadas.
EP0597016A4 (en) Infectious bursal disease virus recombinant poxvirus vaccine.
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
WO2002035981A3 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
CA2198743A1 (en) Feline infectious peritonitis vaccine
EP1021526A4 (en) RECOMBINANT, GENETICALLY DELETED, PROVIRAL FeLV-DNA FOR THE PRODUCTION OF VACCINALS AGAINST FeLV.
FR2709132B1 (fr) Fragment d&#39;ADN portant le gène codant pour l&#39;enzyme de fragmentation du N-acétylhéparosane et les séquences adjacentes permettant son expression, enzyme recombinée et son utilisation.
ATE374622T1 (de) Genetische impstoffe mit adjuvans

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]